18.01
-4.73 (-20.80%)
| Previous Close | 22.74 |
| Open | 22.45 |
| Volume | 455,532 |
| Avg. Volume (3M) | 422,374 |
| Market Cap | 965,274,752 |
| Price / Sales | 529.00 |
| 52 Weeks Range |
| Operating Margin (TTM) | -3,112.52% |
| Diluted EPS (TTM) | -1.36 |
| Quarterly Revenue Growth (YOY) | -2.30% |
| Total Debt/Equity (MRQ) | 0.88% |
| Current Ratio (MRQ) | 20.90 |
| Operating Cash Flow (TTM) | -55.67 M |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Upstream Bio, Inc. | - | - |
Stockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.88 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 19.25% |
| % Held by Institutions | 61.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (Piper Sandler, 316.44%) | Buy |
| Median | 56.50 (213.72%) | |
| Low | 38.00 (JP Morgan, 110.99%) | Buy |
| Average | 56.50 (213.72%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 27.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 05 Nov 2024 | 38.00 (110.99%) | Buy | 27.39 |
| Piper Sandler | 05 Nov 2024 | 75.00 (316.44%) | Buy | 27.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Nov 2024 | Announcement | Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
| 15 Oct 2024 | Announcement | Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |